Stocktoria
BioXcel Therapeutics, Inc. BTAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-08
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — |
| Operating income | -$50.5M | -$67.2M | -$171.8M | -$159.6M | -$106.9M |
| Net income | -$69.9M | -$59.6M | -$179.1M | -$165.8M | -$106.9M |
| Operating cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.3M | -$82.2M |
| Free cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.5M | -$82.6M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M |
| Shareholders' equity | -$95.5M | -$93.1M | -$56.5M | $76.8M | $221.7M |
| Ratios | |||||
| Operating margin | -7860.0% | -2967.6% | -12448.0% | -42572.0% | — |
| Net margin | -10887.4% | -2630.1% | -12974.9% | -44201.9% | — |
| FCF margin | -8974.3% | -3178.6% | -11233.8% | -36128.0% | — |
| Return on assets | -155.6% | -155.5% | -242.9% | -80.5% | -44.7% |
| Return on equity | 73.2% | 64.0% | 316.9% | -215.9% | -48.2% |
| Debt / equity | -1.15× | -1.10× | -1.78× | 1.21× | — |
| Current ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 |
| Revenue growth | -71.7% | 64.2% | 268.0% | — | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001720893 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.